S&P 500 headed for sixth straight decline as J&J advanced two products

As of CNBC Investing Club’s November 19, 2026, afternoon report, the S&P 500 was on pace for a sixth consecutive decline. The index was roughly 7% below its October 6 record close of 7,818.93. The session had not ended, so a sixth decline was not yet confirmed.

The report also highlighted two developments at Johnson & Johnson. Memorial Hermann–Texas Medical Center in Houston was set to become the first hospital to commercially install J&J’s Ottava robotic surgical system. The hospital participated in Ottava’s clinical trials, and the FDA authorized the system in July 2026 for 10 upper-abdominal general surgery procedures.

Separately, J&J submitted Caplyta to the FDA for approval to treat manic episodes associated with bipolar I disorder. The submission followed two late-stage studies in which the drug reduced manic symptoms compared with a placebo as early as day three, with improvements sustained through week three. This use remains under review; it has not been approved.

Caplyta is already approved for several adult uses, including depressive episodes associated with bipolar I and II disorders. Its third-quarter revenue rose 66% from a year earlier to $398 million, according to the report, and 2026 sales had exceeded $1 billion. J&J shares were down about 7% from their record close the previous Friday despite the product news.